Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil Sells 8,000 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 8,000 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the transaction, the chief operating officer now owns 154,931 shares in the company, valued at approximately $11,351,794.37. This trade represents a 4.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Jim Wassil also recently made the following trade(s):

• On Monday, February 3rd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $86.22, for a total value of $689,760.00.
• On Thursday, January 2nd, Jim Wassil sold 8,000 shares of Vaxcyte stock. The stock was sold at an average price of $83.66, for a total value of $669,280.00.

Vaxcyte Stock Performance

PCVX stock opened at $73.89 on Thursday. Vaxcyte, Inc. has a 1 year low of $58.10 and a 1 year high of $121.06. The firm has a market cap of $9.51 billion, a P/E ratio of -16.06 and a beta of 1.02. The stock has a 50-day simple moving average of $83.74 and a 200-day simple moving average of $94.70.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.14. On average, equities research analysts predict that Vaxcyte, Inc. will post -4.21 EPS for the current year.

Institutional Investors Weigh In On Vaxcyte

Hedge funds have recently bought and sold shares of the business. Whipplewood Advisors LLC acquired a new stake in Vaxcyte during the 4th quarter valued at approximately $28,000. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 188.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares in the last quarter. National Bank of Canada FI acquired a new stake in Vaxcyte during the 4th quarter valued at approximately $41,000. Blue Trust Inc. grew its stake in Vaxcyte by 100.0% during the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after purchasing an additional 371 shares in the last quarter. Finally, Assetmark Inc. grew its stake in Vaxcyte by 77,500.0% during the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after purchasing an additional 775 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Vaxcyte in a report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Guggenheim restated a “buy” rating and issued a $160.00 price objective on shares of Vaxcyte in a report on Wednesday, February 26th. Finally, The Goldman Sachs Group began coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price for the company. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $147.50.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.